Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBTX advanced for three days, in of 167 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on March 25, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 43 cases where NBTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on April 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NBTX turned negative on April 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .
NBTX moved below its 50-day moving average on April 02, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NBTX broke above its upper Bollinger Band on March 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBTX entered a downward trend on March 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (3.729) is also within normal values, averaging (252.036).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FCDCX | 27.90 | N/A | N/A |
Fidelity Advisor Stock Selector Sm Cp C | |||
GTDFX | 33.29 | N/A | N/A |
Invesco EQV Emerging Markets All Cap R6 | |||
TIHJX | 12.44 | N/A | N/A |
Transamerica International Stock R6 | |||
MGKAX | 11.70 | N/A | N/A |
Morgan Stanley Global Permanence A | |||
FCEEX | 10.62 | N/A | N/A |
Franklin Emerging Market Core Equity Adv |
A.I.dvisor tells us that NBTX and PBYI have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBTX and PBYI's prices will move in lockstep.
Ticker / NAME | Correlation To NBTX | 1D Price Change % | ||
---|---|---|---|---|
NBTX | 100% | -5.03% | ||
PBYI - NBTX | 28% Poorly correlated | +2.73% | ||
GLMD - NBTX | 26% Poorly correlated | +5.63% | ||
CRMD - NBTX | 25% Poorly correlated | +3.79% | ||
GLPG - NBTX | 24% Poorly correlated | -1.09% | ||
OTLK - NBTX | 23% Poorly correlated | +2.46% | ||
More |